Clinical Trials
57 trialsPhase 1 Study of CLR 125 in Triple Negative Breast Cancer
Cellectar Biosciences, Inc.
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
NEXUS-01
Eli Lilly and Company
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
University of Southern California
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Novartis
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Aktis Oncology, Inc.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
DELTA-101
Exelixis
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
PAveMenT
Royal Marsden NHS Foundation Trust
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Epsilogen Ltd
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Mabwell (Shanghai) Bioscience Co., Ltd.
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc.
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Accent Therapeutics
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
ProteinQure Inc.
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo, Inc.
ASTEROID
Institute of Cancer Research, United Kingdom
DecipHER
H. Lee Moffitt Cancer Center and Research Institute
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
ON-5001
OncoNano Medicine, Inc.
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
University of Illinois at Chicago
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
Xijing Hospital
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Monopar Therapeutics
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
Monopar Therapeutics